(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €52.90 | 2.06% | 8.13% |
| MEDISTIM (MEDI.OL) | kr222.00 | 1.96% | 31.89% |
| BIOMERIEUX (BIM.PA) | €96.42 | 0.92% | 9.87% |
| VETOQUINOL (VETO.PA) | €90.50 | 0.91% | 10.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
2.06% Forward Dividend Yield and 8.13% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.89.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 18.3. Meaning, the purchaser of the share is investing €18.3 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
Moving Average
BOIRON’s worth is above its 50-day moving average of €50.43 and way higher than its 200-day moving average of €44.26.
More news about BOIRON.
2. MEDISTIM (MEDI.OL)
1.96% Forward Dividend Yield and 31.89% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.32.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 35.13. Meaning, the purchaser of the share is investing kr35.13 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Volume
Today’s last reported volume for MEDISTIM is 16083 which is 589.66% above its average volume of 2332.
Sales Growth
MEDISTIM’s sales growth is 16.7% for the ongoing quarter and 5.1% for the next.
Moving Average
MEDISTIM’s worth is way under its 50-day moving average of kr257.26 and way below its 200-day moving average of kr251.43.
Volatility
MEDISTIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.21%, a negative 0.74%, and a positive 2.48%.
MEDISTIM’s highest amplitude of average volatility was 5.48% (last week), 3.04% (last month), and 2.48% (last quarter).
More news about MEDISTIM.
3. BIOMERIEUX (BIM.PA)
0.92% Forward Dividend Yield and 9.87% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.82.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 25.24. Meaning, the purchaser of the share is investing €25.24 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.87%.
Volume
Today’s last reported volume for BIOMERIEUX is 6224 which is 92.25% below its average volume of 80379.
Volatility
BIOMERIEUX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.68%, a negative 0.11%, and a positive 1.11%.
BIOMERIEUX’s highest amplitude of average volatility was 1.33% (last week), 1.10% (last month), and 1.11% (last quarter).
Moving Average
BIOMERIEUX’s value is above its 50-day moving average of €94.41 and higher than its 200-day moving average of €95.73.
More news about BIOMERIEUX.
4. VETOQUINOL (VETO.PA)
0.91% Forward Dividend Yield and 10.37% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.06.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 22.29. Meaning, the purchaser of the share is investing €22.29 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
Yearly Top and Bottom Value
VETOQUINOL’s stock is valued at €90.50 at 17:30 EST, way under its 52-week high of €113.80 and way higher than its 52-week low of €77.00.
More news about VETOQUINOL.
